CRL director granted 1,438 shares of stock

Charles River Laboratories director Abraham Ceesay received a stock-based compensation award.

Rhea-AI Filing Summary

Charles River Laboratories director Abraham Ceesay received a stock-based compensation award. On 5/8/2026, he acquired 1,438 shares of Common Stock at $177.62 per share as a grant or award, bringing his directly held stake to 2,384 shares. The related unvested restricted stock units vest on the earlier of May 8, 2027 or the business day prior to the company’s next annual meeting of shareholders, tying the award to continued service and future company performance rather than an open-market purchase.

Insights

Equity Compensation Analyst

Routine director equity grant aligning incentives; limited signaling value.

This Form 4 shows director Abraham Ceesay receiving 1,438 shares of Charles River Laboratories Common Stock as a grant at $177.62 per share. The transaction is coded as an acquisition from compensation, not an open-market purchase.

The footnote states unvested restricted stock units vest on the earlier of May 8, 2027 or the business day prior to the next annual meeting. This structure encourages ongoing board service and alignment with shareholders, but does not reflect an active buy decision.

Following the award, Ceesay directly holds 2,384 shares, so the grant represents a substantial addition relative to his prior holdings. Future company filings may clarify any additional equity awards or changes in his ownership position over time.

Insider Trade Summary

Grant/Award: 1,438 shares

Grant/Award 1 txn

Insider Ceesay Abraham

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,438	$177.62	$255K

Holdings After Transaction: Common Stock — 2,384 shares (Direct)

Footnotes (1)

1. F1. The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.

Key Figures

Shares granted: 1,438 shares Grant reference price: $177.62 per share Shares held after grant: 2,384 shares +1 more

4 metrics

Shares granted 1,438 shares Common Stock award on May 8, 2026

Grant reference price $177.62 per share Common Stock grant to director

Shares held after grant 2,384 shares Director’s direct ownership following transaction

Vesting date trigger May 8, 2027 RSUs vest earlier of this date or before next annual meeting

Key Terms

restricted stock units, grant/award acquisition, Common Stock, Form 4

4 terms

restricted stock units financial

"The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

grant/award acquisition financial

"transaction_action": "grant/award acquisition""

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Abraham Ceesay report in the latest CRL Form 4 filing?

Abraham Ceesay reported receiving 1,438 shares of Charles River Laboratories Common Stock as a grant at $177.62 per share. This award increased his direct holdings to 2,384 shares and reflects stock-based compensation rather than an open-market stock purchase.

Is the Abraham Ceesay CRL Form 4 transaction a stock purchase or compensation grant?

The transaction is a compensation grant, coded as an award acquisition rather than an open-market purchase. Ceesay received 1,438 Common Stock shares at $177.62 per share, increasing his direct position to 2,384 shares without signaling an active buy decision in the open market.

How many Charles River Laboratories shares does Abraham Ceesay hold after this Form 4?

After the reported transaction, Abraham Ceesay directly holds 2,384 shares of Charles River Laboratories Common Stock. This follows a grant of 1,438 shares at $177.62 per share, meaning the award significantly increased his ownership compared with his pre-grant holdings.

When do Abraham Ceesay’s unvested restricted stock units in CRL vest?

The unvested restricted stock units vest on the earlier of May 8, 2027, or the business day before the company’s next annual shareholder meeting. This schedule links vesting to both time and corporate governance events, encouraging continued service on Charles River Laboratories’ board.

Does Abraham Ceesay’s Form 4 indicate any Charles River Laboratories stock sales?

No stock sales are reported in this Form 4. The filing shows only an acquisition of 1,438 Common Stock shares as a grant at $177.62 per share, raising his direct holdings to 2,384 shares, with no dispositions or sales disclosed in the transaction summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 04:51 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ceesay Abraham

(Last) (First) (Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON MASSACHUSETTS 01887

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/08/2026		A		1,438(1)	A	$177.62	2,384	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.

	/s/ Abraham Ceesay	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)